Docking de fragmentos aplicados no desenvolvimento de inibidores tirosina quinase em leucemia mieloide crônica

• Ano de defesa: 2015
• Autor(a) principal: Pereira, Washington De Almeida
• Orientador(a): Camps Rodríguez, Ihosvany
• Banca de defesa: Veloso, Márcia Paranho, Arcuri, Helen Andrade
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal de Alfenas
• Programa de Pós-Graduação: Programa de Pós-Graduação em Química
• Departamento: Instituto de Ciências Exatas
• País: Brasil
• Palavras-chave em Português: Leucemia Mieloide Crônica BRC-ABL Positiva; Proteínas Tirosina Quinase; Proteínas de Ancoragem à Quinase A
• Área do conhecimento CNPq: CIENCIAS EXATAS E DA TERRA
• Link de acesso: https://repositorio.unifal-mg.edu.br/handle/123456789/714

Chronic myeloid leukemia is associated with hematopoietic stem cell disorder that manifests itself primarily with myelopoiesis the expansion. The Philadelphia chromosome positive PH is generated by a reciprocal translocation (9, 22) (q34, q11), and by the merger of the Abelson gene fusion that encodes and deregulates quinase Tyrosine protein enough for the initiation and maintenance of disease. Tyrosine quinase provides a therapeutic target, which used to inhi- bition of this protein Known as tyrosine Quinase. Inhibitors such as Imatinibe mesylate has revolutionized the treatment of patients with chronic myeloid leukemia. Mutations in domain quinase Bcr-Abl, constituting the most frequent mechanism acquired resistance to therapy with tyrosine quinase. The T315I mutation and currently biggest challenge for maintenance of chro- nic myeloid leukemia in chronic phase, since inhibitors of tyrosine Quinase currently found on the market are unable to it maintaining it in a controlled manner, leading the patient achieved. Methods based on fragment docking emerged as a new strategy for drug discovery. evaluating all possible input locations and connecting the inhibitor and protein, and thus may provide a new molecule will be able to make effective inhibition. The docking studies are divided into three parts. At first, the fragments are placed to interact within the possible interaction sites. In the second step, the molecules are created from the best fragments which interacted with a particular website. In the last step, the study of molecules created in the docking site using the protocols of Induced Fit Docking which performs flexible, flexible docking ie flexible linker protein is made flexible.